Unlocking Blood-Brain Barrier Boosts Immunotherapy Efficacy, Lowers ARIA
Roche’s “brain shuttle” antibody, trontinemab, cleared plaque in Phase 1 with little ARIA, highlighting that bypassing vascular amyloid could be the key.
ALL NEWS
6541 RESULTS
Sort By:
- Most Recent
- Most Commented
After Long Wait, Aβ Oligomer Detangler Poised for Phase 2
Phase 1b results tease that the small molecule PRI-002 might curb cognitive decline. Phase 2 is slated for early 2024.
Moving Forward: RNA-Targeted Attempts at Taking Down Tau, APP
In early phase trials, therapy lowering tau translation hinted at cognitive benefit, while going after APP lowered its fragments and Aβ peptides.
Treat Before ‘Aβ Bothers Tau,’ Scientists Say at CTAD
At trials conference, multiple amyloid immunotherapy programs reported greatest cognitive benefits for people whose tau tangle deposition has only just begun.
Clinical Trials on Alzheimer's Disease (CTAD) 2023- 16th
To Recruit for Diverse Alzheimer Trials, Go to the People From St. Louis to Boston, Scientists Grapple with Ethnoracial Divide in AD Biomarkers Treat Before ‘Aβ Bothers Tau,’ Scientists Say at CTAD Moving Forward: RNA-Targeted Attempts at Taking Down Tau,
From St. Louis to Boston, Scientists Grapple with Ethnoracial Divide in AD Biomarkers
Across several studies, black/African Americans and Hispanic or Latino people had lower amyloid positivity rates than whites. Scientists are studying why.
To Recruit for Diverse Alzheimer Trials, Go to the People
Most participants in AD research studies and trials are non-Hispanic whites. At a conference in St. Louis, scientists discussed strategies to include diverse populations.
Border Surprise: Glia Limitans Astrocytes Sit on Brain Surface
A new study defined the location and expression profile of this astrocyte subtype, pegging the protein myocilin as a marker.
Amyloid, Not Vascular Disease, May Drive White-Matter Hyperintensities
These imaging abnormalities grew the most in people with many plaques or cerebral amyloid angiopathy pathology, irrespective of cardiovascular risk.
Is Transgelin-2 a ‘Receptor’ for Soluble TREM2?
Scientists report that when the TREM2 fragment binds transgelin-2, it weakens phosphorylation of tau in neurons.
Can Flipping a Lipid Switch Protect the Brain?
At Leiden conference, scientists discussed how shifting cells toward “specialized pro-resolving mediators” could counter inflammation.
In Amyloid and Tangle Models, APOE4 Paralyzes Microglia
The Alzheimer’s risk allele locks microglia in a state of homeostasis. They ignore amyloid plaques and neurofibrillary tangles.
New Therapeutic Strategy—Mimic the ApoE Christchurch Mutation?
An antibody copying the effects of the protective ApoE variant prevents tau hyperphosphorylation in the mouse eye and brain.
Cracking the Cholesterol-AD Code: Metabolites and Cell Type
A cholesterol metabolite magnifies pathology in a tauopathy mouse. Microglia need cholesterol to rein in amyloid. ApoE4 jams the fat's export from neuron to glia.
Does the Brain Use Microglia to Maintain Its Myelin?
We all know oligodendrocytes maintain myelin. According to scientists at the 2nd Symposium on Lipids in Diseases, they need microglia to do it.
Current Filters
No filters selected